E2F4 plays a key role in Burkitt lymphoma tumorigenesis
Molina-Privado I et al. – Enforced E2F4 expression in BL cells not only diminishes E2F1 levels, but also reduces selectively the tumorigenic properties and proliferation of BL cells, while increasing their accumulation in G2/M. E2F4 may serve as a target for developing novel and less toxic treatments for sBL.
Proteins whose expression or function is deregulated in sBL and play a role in its formation which could facilitate development of less toxic therapies were identified.
E2F sites in its promoter fail to repress its transcriptional activity in BL cells and that the transcriptional repressor E2F4 barely interacts with these sites.
E2F4 protein levels, but not those of its mRNA, are reduced in sBL cell lines relative to immortal B-cell lines.
E2F4 protein expression is also decreased in 24 of 26 sBL tumor samples from patients compared with control tissues.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.